0001179110-21-008894.txt : 20210922
0001179110-21-008894.hdr.sgml : 20210922
20210922175644
ACCESSION NUMBER: 0001179110-21-008894
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210921
FILED AS OF DATE: 20210922
DATE AS OF CHANGE: 20210922
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KANGO SUJAY
CENTRAL INDEX KEY: 0001336503
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36065
FILM NUMBER: 211270419
MAIL ADDRESS:
STREET 1: 1028 CHAMBERS COURT
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACCELERON PHARMA INC
CENTRAL INDEX KEY: 0001280600
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-649-9200
MAIL ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
FORM 4 -
X0306
4
2021-09-21
0
0001280600
ACCELERON PHARMA INC
XLRN
0001336503
KANGO SUJAY
128 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
EVP, Chief Commercial Officer
Common Stock
2021-09-21
4
M
0
5000
40.61
A
23509
D
Common Stock
2021-09-21
4
S
0
5000
150.03
D
18509
D
Option to Purchase Common Stock
40.61
2021-09-21
4
M
0
5000
0
D
2028-03-01
Common Stock
5000
30000
D
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.45 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The shares of common stock underlying this stock option award vested as to 25% of the shares on the first anniversary of February 12, 2018 and the remaining shares vest in equal quarterly installments over the following three years thereafter.
/s/ Adam M. Veness, as attorney-in-fact for Sujay Kango
2021-09-22